532406-56-7

Upstream product

• 35674-27-2 4-iodo-3-nitrobenzoic acid 
• 1588-83-6 4-amino-3-nitrobenzoic acid 
• 27329-27-7 4-methyl-2-nitrobenzoic acid 
• 5326-39-6 4-iodo-3-nitrotoluene 

Downstream Products

• 17319-37-8 O-(4-iodo-3-nitro-benzoyloxy)-ergocalciferol 
• 875271-83-3 [5-(4-iodo-3-nitro-benzoyl)-2-phenyl-thiophen-3-yl]-acetic acid methyl ester 
• 1004752-86-6 methyl 2-(2-bromo-5-(4-iodo-3-nitrobenzoyl)thiophen-3-yl)acetate 
• 1374326-50-7 Ethyl 2-(2-bromo-5-(4-iodo-3-nitrobenzoyl)thiophen-3-yl)acetate 
• 1374035-40-1 N-methyl-4-(2-(trimethylsilyl)ethynyl)-3-nitrobenzamide 
• 1374035-16-1 N-methyl-4-ethynyl-3-nitrobenzamide 
• 1374035-34-3 N-methyl-4-cyano-3-nitrobenzamide 
• 1374035-39-8 N-methyl-4-iodo-3-nitrobenzamide 
• 160003-66-7 4-iodo-3-nitrobenzamide 
• 875271-82-2 (5-{3-[(tert-butoxycarbonyl)amino]-4-iodobenzoyl}-2-phenylthiophene-3-yl)acetic acid 
• 1021171-80-1 [5-(3-tert-butoxycarbonylamino-4-iodo-benzoyl)-2-phenyl-thiophen-3-yl]-acetic acid methyl ester 
• 875271-81-1 [5-(4-iodo-3-nitrobenzoyl)-2-phenylthiophen-3-yl]acetic acid 
• 875271-84-4 [5-(3-amino-4-iodo-benzoyl)-2-phenyl-thiophen-3-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

Inexpensive NaX (X = I, Br, Cl) as a halogen donor in the practical Ag/Cu-mediated decarboxylative halogenation of aryl carboxylic acids under aerobic conditions

Versatile and practical Ag/Cu-mediated decarboxylative halogenation between readily available aryl carboxylic acids and abundant NaX (X = I, Br, Cl) has been achieved under aerobic conditions in moderate to good yields. The halodecarboxylation is shown to be an effective strategy for S-containing heteroaromatic carboxylic acid and benzoic acids with nitro, chloro and methoxyl substituents at the ortho position. A gram-scale reaction and a three-step procedure to synthesize iniparib have been performed to evaluate the practicality of this protocol. A preliminary mechanistic investigation indicates that Cu plays a vital role and a radical pathway is involved in the transformation.

NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT

The invention is directed to new class of quinolone heterocyclic aromatic molecules (Renotinibs) and their use in the treatment of cancer, in particular, cancer that harbor abnormal human epidermal growth factor receptors (EGFRs).

The flocculated acryloyldimethyltauric molecule ligand

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

BENZAMIDE DERIVATIVE WITH ANTICANCER ACTIVITY AND PREPARATION METHOD AND USE THEREOF

Provided are a benzamide derivative as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the preparation method and use thereof for preparing a medicine for treating cancer, wherein the group definitions of formula (I) are as set out

SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS

Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors.

Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A

Botulinum neurotoxin serotype A (BoNTA) is one of the most toxic substances known. Currently, there is no antidote to BoNTA. Small molecules identified from high-throughput screening reportedly inhibit the endopeptidase-the zinc-bound, catalytic domain of